

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Revive Therapeutics Ltd. (the "Issuer")

Trading Symbol: RVV

Number of Outstanding Listed Securities: 230,424,637

Date: September 3rd, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer disseminated 6 news releases during the month:-

- (i) **Aug. 5: Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19;**

- (ii) **Aug. 11: Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics – Developed Prototypes of Orally Dissolvable Thin Film For Psilocybin;**
- (iii) **Aug. 14: Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19;**
- (iv) **Aug. 19: Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID19 in Asia-Pacific and Canada;**
- (v) **Aug. 26: Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19 – Revive to also explore FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19;**
- (vi) **Aug. 31: Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19.**

The above were filed on the CSE website and at www.sedar.com.

2. Provide a general overview and discussion of the activities of management.

See item #1.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not Applicable

Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not Applicable

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See item #1.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not Applicable

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not Applicable

7. Describe the acquisition of new customers or loss of customers.

Not Applicable

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not Applicable

9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not Applicable

10. Report on any labour disputes and resolutions of those disputes if applicable.

Not Applicable

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

No developments; see Contingency note in Consolidated Financial Statements as of and for the year ended June 30, 2019 and Management Discussion and Analysis (MD&A) filed on the SEDAR website at www.sedar.com.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not Applicable

13. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common Shares	13,134,266	Warrant and stock option exercises x18	for general corporate purposes

(1) State aggregate proceeds and intended allocation of proceeds.

Provide details of any loans to or by Related Persons.

Not Applicable

14. Provide details of any changes in directors, officers or committee members.

Not Applicable

15. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

See Item #1.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there was no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **September 3rd, 2020**

Michael Frank

Name of Director or Senior Officer

"Michael Frank"

Signature

Chairman and CEO

Official Capacity

<i>Issuer Details</i>		For Month	Date of Report
Name of Issuer		End	YY/MM/DD
Revive Therapeutics Ltd.		August	20/09/03
Issuer Address			
82 Richmond Street East			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Toronto, Ontario M5C 1P1		416 848 0790	416 848 7744
Contact Name		Contact Position	Contact Telephone No.
Michael Frank		CEO	647 985 2336
Contact Email Address		Web Site Address	
mfrank@revivethera.com		www.revivethera.com	